For instance, the genetic loss of the β-2-microglobulin (B2M) gene, the structural component of MHC class I complexes, is enriched in pre-treatment tumor samples from melanoma patients with innate and acquired resistance to checkpoint inhibitor therapy (12, 13). This evidence concerns the gene B2M and melanoma.